[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100375311":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":36,"centralContacts":36,"locations":37,"responsibleParty":65,"collaborators":36,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":36,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":36,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":40,"whyStopped":36,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Jagiellonian University","OTHER",[8,14,18,22,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Long protocol","ACTIVE_COMPARATOR","Ovarian hyperstimulation started on day 2 or 3 of the cycle with daily subcutaneous injections of recombinant human FSH (follitropin α, Gonal F®, Merck Serono) and\u002For urinary human menopausal gonadotropin (menotropin, Menopur®, Ferring GmbH) or mixed recombinant human FSH\u002FLH (Pergoveris®, Merck Serono) with a starting dose of 87.5-250 IE\u002Fday",[13],"Diagnostic Test: fibrin clot properties",{"label":15,"type":10,"description":16,"interventionNames":17},"Short protocol","Ovarian hyperstimulation with a GnRH-antagonist consisted of the use of ganirelix (Orgalutran®, MSD) from the 6th day of stimulation until it's end at the daily dose of 0.25 mg",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Clomiphene citrate","Ovarian stimulation with clomiphene citrate (Clostilbegyt®, EGIS) 50 mg daily per os form 3rd to 7th day of the cycle",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Letrozole","Ovarian stimulation with letrozole (Lametta®, Vipharm) 2.5 mg daily per os form 3rd to 7th day of the cycle",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Gonadotropins","Ovarian hyperstimulation started on day 2 or 3 of the cycle with daily subcutaneous injections of recombinant human FSH (follitropin α, Gonal F®, Merck Serono).",[13],[31],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"DIAGNOSTIC_TEST","fibrin clot properties","Assessment of thrombin generation and efficiency of fibrinolysis.",[19,27,23,9,15],null,[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Department of Gynecological Endocrinology Jagiellonian University Medical College","RECRUITING","Krakow","Małopolska","30-501","Poland","PL",{"type":47,"coordinates":48},"Point",[49,50],19.93658,50.06143,{"lat":50,"lon":49},[53,58,61,63],{"name":54,"role":55,"phone":56,"phoneExt":36,"email":57},"Magdalena Piróg, MD, PhD","CONTACT","604514915","magda.m.pulka@gmail.com",{"name":59,"role":60,"phone":36,"phoneExt":36,"email":36},"Olga Kacalska - Janssen, MD, PhD","SUB_INVESTIGATOR",{"name":62,"role":60,"phone":36,"phoneExt":36,"email":36},"Joanna Natorska, MD, PhD",{"name":64,"role":60,"phone":36,"phoneExt":36,"email":36},"Robert Jach, MD, PhD",{"type":66,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":36,"oldOrganization":36},"PRINCIPAL_INVESTIGATOR","Magdalena Piróg, MD","Principal Investigator","100375311","ovarian-hyperstimulation-and-fibrin-clot-properties-100375311",false,"NCT04166825","Ovarian Hyperstimulation and Fibrin Clot Properties.","The Impact of Different Ovarian Hyperstimulation Protocols on Coagulation and Fibrinolysis.","Inclusion Criteria:\n\n* infertility defined based on the WHO 2010 criteria\n\nExclusion Criteria:\n\n* ovarian involvement\n* oral contraceptives use within previous 3 months\n* dienogest therapy within 3 months until ART\n* thrombotic events in the medical history\n* severe hypertension\n* diabetes mellitus\n* the presence of known VTE risk factors, including obesity, recent major surgery with prolonged immobilization or trauma,\n* deficiency of antithrombin, protein C or protein S,\n* antiphospholipid syndrome,\n* known malignancy,\n* any chronic inflammatory diseases (e.g. rheumatoid arthritis)\n* advanced chronic renal disease (estimated glomerular filtration rate \\[eGFR\\] \\\u003C30 ml\u002Fmin),\n* international normalized ratio (INR) more than 1.2 at the day of blood draw\n* pregnancy.","FEMALE","18 Years","40 Years",{"count":80,"type":81},300,"ESTIMATED","INTERVENTIONAL",[84],"NA","The impact evaluation of ovarian hyperstimulation on coagulation and fibrinolysis in infertile women.\n\nComparative analysis between different ovarian stimulation protocols on thrombin formation and efficiency of fibrinolysis in women diagnosed with infertility.",[87,88,89],"Fibrin Blood Clot","Infertility, Female","Endometriosis",[91,92,93,94],"coagulation","fibrinolysis","ovarian hyperstimulation","infertility","2025-11-28",{"date":97,"type":98},"2025-12-05","ACTUAL",{"date":100,"type":98},"2019-11-18",{"date":102,"type":81},"2026-01",{"name":5,"class":6},1]